ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
Operating income was $6.2 million in the first quarter of fiscal 2025, compared to $9.7 million in the prior year period. This led to net earnings in Q1 ’25 of $5.1 million, compared to $7.3 million ...